Alignment Healthcare (ALHC) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue rose 36.7% year over year to about $1.36 billion, topping the roughly $1.31 billion consensus estimate.
• GAAP (Generally Accepted Accounting Principles) EPS (earnings per share) came in at -$0.04, in line with consensus but a reversal from a $0.02 profit in the same quarter last year.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of about $21.8 million slightly missed expectations, and management cut its full-year EBITDA outlook.
• Health plan membership reached 301,200, up from 294,100 in the prior quarter, driven by continued demand.
• Management cited higher-than-expected medical cost trends, including inpatient and skilled nursing facility costs, as a key headwind.
• Shares traded lower in after-hours activity following the report and the reduced full-year guidance.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover automated trading strategies and ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Alignment Healthcare, a California-based Medicare Advantage insurer, entered this report under pressure. The company had posted a profitable second quarter, but sentiment soured sharply in October after CMS (the Centers for Medicare & Medicaid Services) released 2027 star ratings that analysts believe downgraded the company's largest contract from 4.0 to 3.5 stars, threatening quality bonus payments. Several analysts also flagged near-term headwinds from acute hospital billing and skilled nursing facility costs. Against that backdrop, investors were closely watching whether medical cost trends would validate those concerns and how management would frame its 2027 strategy, making this quarterly earnings release a critical test of the company's growth story.

Reported Results

For the third quarter ended September 30, 2026, Alignment Healthcare reported total revenue of roughly $1.36 billion, up 36.7% year over year and above the consensus estimate of about $1.31 billion. GAAP EPS was -$0.04, in line with consensus but down from a $0.02 profit a year earlier. Net loss attributable to the company was approximately $8.1 million, compared with net income of about $3.7 million in the prior-year quarter.

Adjusted EBITDA of approximately $21.8 million narrowly missed the roughly $22.3 million consensus, reflecting higher medical expenses. The company guided fourth quarter revenue to a midpoint of about $1.32 billion, slightly below the consensus of about $1.33 billion, and lowered its full-year EBITDA guidance to a midpoint of roughly $100 million, well below the consensus of about $147.8 million. Membership grew to 301,200 members, up from 294,100 in the second quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings momentum and shifting sentiment in names like ALHC, the AI Screener offers a practical way to surface relevant opportunities across the broader market.

Market Reaction and Investor Sentiment

The stock traded lower in after-hours activity following the report, as the revenue beat was overshadowed by reduced forward guidance and the lingering star-ratings overhang. Sentiment had already deteriorated sharply entering the quarter, with several analysts downgrading the stock and cutting price targets after the CMS star-ratings release. The combination of softer fourth-quarter revenue guidance, a significantly lower full-year EBITDA outlook, and management's acknowledgment that medical trends ran higher than expected reinforced investor caution about near-term profitability.

Forward Outlook and Key Factors to Monitor

Management framed the guidance reduction as a prudent response to current headwinds, noting that the revised outlook does not assume any benefit from ongoing corrective actions. Chairman and CEO John Kao emphasized execution as the immediate priority, stating the company is confident it can deliver against the lowered expectations.

Investors will be watching several factors in the months ahead. First, the persistence of utilization pressures—particularly inpatient admissions and skilled nursing facility costs—will be critical in determining whether the cost headwinds are temporary or structural. Second, the company's legal challenge to the 2027 star-ratings downgrade remains a key uncertainty, given that a favorable outcome could restore quality bonus payments that analysts estimate carry a significant future earnings impact.

Third, the company's 2027 strategy and any mitigation efforts, including shared risk arrangements and potential benefit adjustments, will be closely scrutinized as bids for the coming plan year take shape. Finally, ongoing membership growth and the company's expansion into new markets will indicate whether demand momentum can offset margin pressures. The next several quarters will test whether Alignment Healthcare can contain costs while sustaining its rapid growth trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations